Financial Performance - Total Q2 Revenue reached $63.2 million[6], with MACI contributing $53.5 million[6], Epicel $8.6 million[6], and NexoBrid $1.2 million[6] - MACI revenue experienced a growth of 21% reaching $53.5 million[10] - Gross margin increased to 74%, up over 400 bps compared to Q2 2024[10] - Adjusted EBITDA increased by 112% to $13.4 million[10] - The company holds $164 million in cash and investments[10] Business Highlights - Approximately 600 surgeons have been trained on MACI Arthro to date[10] - MACI implants for small femoral condyle defects increased by more than 40% in Q2 compared to the prior year[10] - NexoBrid second quarter revenue increased 52% vs prior year[10] - The company received FDA IND clearance for the MACI Ankle clinical study and remains on track to initiate the study in 2H 2025[10] MACI Arthro Launch - MACI Arthro trained surgeons continue to demonstrate expanded MACI utilization[14] - MACI implants for trochlea defects account for nearly 20% of MACI Arthro implants to date[14]

Q2 2025 Financial Performance - Revenue reached $1.1 billion, a 21% year-over-year increase[6] - Bookings totaled $1.4 billion, demonstrating a 51% year-over-year growth[6] - Average Daily Active Users (DAUs) grew to 111.8 million, up 41% year-over-year[6] - Hours Engaged increased to 27.4 billion, a 58% year-over-year rise[6] - Net loss was $(280) million[8] - Net cash provided by operating activities was $199 million, a 32% year-over-year increase[8] - Free cash flow was $177 million, a 58% year-over-year increase[8] Q3 and Fiscal Year 2025 Guidance - Q3 2025 revenue is projected between $1.11 billion and $1.16 billion, representing a 21% to 26% year-over-year increase[63] - Q3 2025 bookings are expected to range from $1.59 billion to $1.64 billion, indicating a 41% to 45% year-over-year growth[63] - Full year 2025 revenue is forecasted between $4.39 billion and $4.49 billion, a 22% to 25% year-over-year increase[64] - Full year 2025 bookings are projected between $5.87 billion and $5.97 billion, reflecting a 34% to 37% year-over-year growth[64]

Financial Performance - Q2 2025 revenue was $415.6 million, a decrease of 0.6% compared to Q2 2024's $418.2 million[37] - Organic revenue decreased by 1.4% to $412.4 million in Q2 2025 compared to $418.2 million in Q2 2024[9, 38] - Adjusted EPS for Q2 2025 was $0.45, a decrease of 28.6% compared to $0.63 in Q2 2024[10, 37] - Adjusted EBITDA margin decreased by 290 bps to 17.1% in Q2 2025 compared to 20.0% in Q2 2024[10, 40] - Adjusted gross margin decreased by 450 bps to 60.7% in Q2 2025 compared to 65.2% in Q2 2024[11, 37] - Operating cash flow was $8.9 million with a negative 32.7% free cash flow conversion in Q2 2025[11, 39] Segment Performance - Codman Specialty Surgical Q2 2025 revenue was $304.0 million, a 0.7% increase, with organic growth down 0.3% to $300.9 million[13] - Tissue Technologies Q2 2025 revenue was $111.6 million, a decrease of 4.1%[18] Guidance - Q3 2025 reported revenue is projected to be between $410 million and $420 million, with organic growth between +7.3% and +9.9%[28] - Full year 2025 reported revenue is projected to be between $1.655 billion and $1.680 billion, with organic growth between +0.6% and +2.1%[29, 30]

Financial Performance - Q2 2025 - Total Operating Revenues reached $1328 million, a 14.5% increase compared to $1160 million in June 2024[22] - Gaming revenue increased by 16.2%, reaching $1096 million compared to $943 million in June 2024[22] - Non-Gaming revenue increased by 7.4%, reaching $233 million compared to $217 million in June 2024[22] - Adjusted Property EBITDA was $378 million, a 24.7% increase compared to $303 million in June 2024[22] - Net Income increased significantly by 826.9%, reaching $9 million compared to a loss of $1 million in June 2024[22] Performance by Property - Q2 2025 - City of Dreams Macau's Adjusted EBITDA was $226 million, a 36.6% increase compared to $165 million in June 2024[22] - Studio City's Adjusted EBITDA was $105 million, a 32.8% increase compared to $79 million in June 2024[22] - City of Dreams Manila's Adjusted EBITDA was $28 million, a 29.8% decrease compared to $40 million in June 2024[22] - City of Dreams Mediterranean and Other's Adjusted EBITDA was $12 million, a 5.3% decrease compared to $13 million in June 2024[22] Sustainability Initiatives - The company aims to achieve carbon-neutral resorts and zero waste across all resorts by 2030[62, 63] - The company installed 25000 solar panels across properties, generating close to 10000 MW annually[66]

Financial Performance & Guidance - Q2 2025 total revenues reached $291 million, a 5% year-over-year increase[79] - The non-GAAP gross margin for Q2 2025 was 44.7%, a 50 bps increase[79] - Non-GAAP EBITDA for Q2 2025 was $38 million, a 4% decrease year-over-year[79] - Non-GAAP diluted earnings per share for Q2 2025 were $0.45, a $0.06 decrease[79] - The company projects total year 2025 revenue between $1.13 billion and $1.16 billion, a 3% year-over-year increase[80] - The company anticipates product bookings between $500 million and $550 million for 2025[86] - The company expects annual recurring revenue (ARR) between $610 million and $630 million for 2025[86] Strategic Focus & Growth - SaaS and Expert Services are targeted to reach 23% of total revenue in 2025[27] - The company has a robust product backlog of $647 million and annual recurring revenue of $580 million as of December 31, 2024[25] - The company is focused on expanding SaaS and Expert Services to capitalize on growth opportunities[29]

Financial Performance - Total revenue increased by 7% year-over-year to $265 billion[53] - Launch products generated $252 million in revenue, a 26% increase quarter-over-quarter and a 91% increase year-over-year[53] - Non-GAAP diluted EPS increased by 4% year-over-year to $547[53] - The company generated $134 million of free cash flow, which includes a $745 million impact from Q2 2025 tax payments[53] - The company expects full-year 2025 Non-GAAP diluted EPS between $1550 and $1600, up from the previous guidance of $1450 to $1550[53] - The company expects full-year 2025 total revenue to be approximately flat at constant currency versus FY 2024, an increase from a mid-single-digit decline previously[53] Product Performance - SKYCLARYS worldwide sales reached $130 million in Q2, up 30% year-over-year and 5% quarter-over-quarter[47] - SKYCLARYS U S sales were $78 million, up 3% year-over-year and 13% quarter-over-quarter[47] - ZURZUVAE U S sales were $46 million in Q2, up 213% year-over-year and 68% quarter-over-quarter[48] - LEQEMBI worldwide sales were $160 million in Q2, excluding $35 million in stocking in China; U S sales increased 20% quarter-over-quarter to $63 million[49] Pipeline and Development - Phase 3 studies were initiated for felzartamab in IgAN and PMN, and for SKYCLARYS in pediatric FA[18] - Positive Phase 1b results for salanersen support moving to registrational status for SMA, with a Phase 3 study expected to start by early 2026[18,32] - New analyses of dapirolizumab pegol Phase 3 data in SLE show improvement in fatigue and reduction in disease activity[18]

Q2 2025 Financial Performance - Net sales decreased by 48% to $2096 million compared to Q2 2024[10, 22] - Adjusted operating income decreased by 209% to $228 million, with the adjusted operating income margin decreasing by 220 basis points to 109%[10, 22] - Adjusted net income decreased by 215% to $114 million, and diluted EPS decreased by 205% to $031[10] - The company generated strong free cash flow of $247 million, an increase of $148 million from the previous year[10] Segment Results - Material Handling net sales decreased by 44% to $1586 million, and adjusted operating income decreased by 109% to $289 million[31] - Distribution net sales decreased by 60% to $510 million, and adjusted operating income decreased by 444% to $16 million[33] Strategic Initiatives and Outlook - The company is launching a strategic review of Myers Tire Supply (MTS), which represents $189 million in sales over the last twelve months (LTM)[13] - The company is consolidating rotational molding production capacity by idling two of nine facilities, expecting at least $3 million in annual savings[15] - The company is tracking to achieve $20 million in cost savings by the end of 2025, primarily in SG&A[15, 41] - The company maintains a capital expenditure target of 3% of sales, focusing on high-growth opportunities[16, 39]

Financial Performance - Codere Online's Q2 2025 Net Gaming Revenue (NGR) reached €54.8 million, a 1% increase compared to Q2 2024, but a 12% increase at constant FX [28] - The company achieved a positive Adjusted EBITDA of €2.3 million in Q2 2025 [28] - Spain's NGR increased by 1% in Q2 2025, reaching €22.1 million [33, 48] - Mexico's NGR increased by 3% in Q2 2025 to €29 million, but increased 23% at constant currency [33, 55] Key Performance Indicators - Average Monthly Actives were approximately 155,000 in Q2 2025, a 7% increase compared to Q2 2024 [28] - The Average Monthly Spend per Active was €118, a 5% decrease compared to Q2 2024 [28] - Codere Online had approximately 277,000 new customer registrations with 78,000 First Time Deposits (FTDs) in Q2 2025, resulting in a 28% Conversion Rate [28] - The Cost per Acquisition (CPA) was €218 in Q2 2025 [28] Outlook - Codere Online projects a 2025 Net Gaming Revenue (NGR) between €220 million and €230 million [78] - The company anticipates an Adjusted EBITDA between €10 million and €15 million for 2025 [78]

Financial Performance - Q2 2025 total revenue reached $154.7 million, an 18% increase at CER (Constant Exchange Rates)[61] - Non-GAAP net income for Q2 2025 was $1.9 million[61] - The company expects to surpass $1 billion in total revenue in FY 2028[6] - The company reiterates FY 2025 total revenue growth guidance of 15% to 22% at CER[65,67] Product Performance - Galafold Q2 2025 revenue was $128.9 million, a 16% increase in reported sales growth[10] - The company anticipates Galafold revenue growth of 10% to 15% for FY 2025 at CER[4,65,67] - Pombiliti + Opfolda Q2 2025 revenue was $25.8 million, a 58% increase at CER[22] - The company anticipates Pombiliti + Opfolda revenue growth of 50% to 65% for FY 2025 at CER[5,25,65,67] Strategic Initiatives - The company acquired U S licensing of DMX-200 Phase 3 Program[4] - The company aims to deliver positive GAAP net income during H2 2025[65,67]

Whitestone REIT's Strategy & Performance - Whitestone focuses on acquiring high total return potential centers, anchoring them to the community, and constantly remerchandising to drive results via capital efficiency[4] - The company targets a Core FFO growth of 4-6%, matched by sustained dividend growth, underpinned by 3-5% Same Store NOI growth[11] - Whitestone aims to enhance Core FFO growth to 5-7% by adding accretive acquisitions with short-term lease up opportunities[11] - The company's strategy involves scaling the Whitestone model to reduce fixed costs and broaden the investor base[11] Financial Highlights & Metrics - Whitestone reported Q2 2025 revenue of $37.9 million, compared to $37.6 million in Q2 2024[8] - Core FFO per share was $0.26 in Q2 2025, up from $0.24 in Q2 2024[8] - Straight Line Leasing Spreads were 17.9% in Q2 2025, compared to 17.5% in Q2 2024[8] - The company's occupancy rate was 93.9% in Q2 2025, slightly up from 93.5% in Q2 2024[8] - Whitestone's Debt/EBITDAre ratio has improved to 7.1x, a 2.0x improvement versus 2021[8] Shop Space & Leasing - 77% of Whitestone's Total Annual Base Rent (ABR) is driven by small shop space tenants under 10,000 square feet[8, 32] - Whitestone's leasing spreads have shown strong performance, with Q2 2025 at 17.9%[5, 8] - The company forecasts a sustainable Same Store NOI growth of 3-5%, driven by contractual escalators (2.3%), leasing (0.8-1.8%), and redevelopment (up to 1.0%)[12, 13] Acquisitions & Dispositions - Whitestone has acquired approximately $153 million in property since Q4 2022, including S Hulen in Ft Worth and San Clemente in Austin in Q2 2025[26] - The company has completed approximately $126 million in dispositions since Q4 2022, including Woodlake in Houston in Q2 2025[26]